Logos Capital

Logos Capital is a San Francisco-based investment firm specializing in biotechnology, employing a data-driven approach to fund transformative therapeutics that advance healthcare standards and deliver strong returns. The firm targets first-in-class and best-in-class companies in private and public markets, particularly at Series B, C, and D stages, using rigorous analysis of clinical trials, operational factors, and commercial potential. Their proprietary Logos Analytics platform models clinical data and predicts trial outcomes to inform precise investment decisions.

Founded in early 2019 by Dr. Arsani William, a Harvard MD and Stanford MBA with prior experience at Farallon Capital Management building its biopharma portfolio, Logos Capital emerged to blend scientific rigor with financial expertise in the biotech sector. William leads as Managing Partner and Chief Investment Officer, supported by partners like Dr. Graham Walmsley (MD, PhD) and Dr. Ed Zhong (PhD), aiming to capitalize on innovations offering functional cures and improved patient access amid evolving therapeutic paradigms.

While specific portfolio details remain limited publicly, Logos Capital has participated in notable financings including RareCyte's $24M round alongside Arboretum Ventures and Agilent Technologies, and Asher Biotherapeutics' $108M Series B led by Wellington Management with RA Capital. The firm also holds significant public positions such as Sarepta Therapeutics and engages in board roles like Design Therapeutics, reflecting a strategy spanning private ventures and public equities for uncorrelated returns.

The team comprises experts in medicine, biology, chemistry, engineering, data science, and finance, including senior analysts like Dr. Yuqi Wang and Dr. Jesse Yu, plus operational leaders such as General Counsel Derek Gould and CFO Cynthia Goldsmith. This multidisciplinary expertise enables comprehensive diligence, from statistical modeling to risk management, positioning Logos Capital to support breakthrough healthcare innovations effectively.